Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AZD4694 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| A | EXPERIMENTAL | \[18F\]4694 |
| Name | Type | Description |
|---|---|---|
| [18F]AZD4694 | DRUG | \[18F\]AZD4694 PET Ligand administered at Visit 1, 30 days following screening and at visit 4 for some of the participants. |
Inclusion Criteria: * Male or female, of any race or/ethnicity * ECG, vital signs, and clinical laboratory values are within normal limits at enrollment or deemed not clinically significant by the physician Exclusion Criteria: * Significant recent (within 6 months) history of neurological (includ...
Top 20 of 24 competitors
AZD4694 is an investigational small molecule being studied for use in Alzheimer's Disease. It is a Phase 2 investigational drug developed by AstraZeneca PLC. The drug is not approved and remains in clinical development.
AZD4694 is a small molecule being studied in Alzheimer's Disease. Its specific molecular target has not been disclosed in available information, so its mechanism of action is not described here.
AZD4694 is being developed by AstraZeneca PLC, a biopharmaceutical company traded on the stock exchange under the ticker AZN. The drug is currently in Phase 2 clinical development for Alzheimer's Disease.
AZD4694 is in Phase 2 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The drug is being studied for Alzheimer's Disease, with one completed Phase 2 trial.
AZD4694 has one completed clinical trial, NCT00991419, titled 'To Compare Positron Emission Tomography (PET) Measurements of Fibrillar Amyloid Burden'. This Phase 2 study enrolled 25 participants in the United States and included healthy volunteers.
AZD4694 is not known to have alternative names. It is a distinct investigational small molecule developed by AstraZeneca PLC for Alzheimer's Disease, currently in Phase 2 clinical development.